Free Newsletter
Wyeth discloses new CEO's salary
Free newsletter via e-mail
Tools
Wonder what a big cheese in Big Pharma earn these days? Well, Wyeth told the Securities & Exchange Commission that it plans to pay its new chief Bernard Poussot (photo) $1.5 million in base salary, plus 120,000 restricted stock units that start vesting in three years. Meanwhile, its non-employee directors will get $220,000 annually in 2008 and 2009.
Remember, though, that base pay is just that. According to Forbes, Wyeth's current CEO, Robert Essner, raked in $25.66 million in 2006, including base pay, bonuses, stock, and perks.
- read the AP report
- see the figures on Essner in Forbes
Related Articles:
Wyeth names Poussot CEO. Report
Wyeth stock down after several setbacks. Report
Wyeth CEO: FDA creating monopoly meds. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
